(Stock Code: 4118)

To Our Shareholders

Report for the
100th Business Period
From April 1, 2023 to March 31, 2024

KANEKA CORPORATIONThe Dreamology Company—M ak e y ou r d re a ms c o me tr u e —Trial & Error experiment driven company
KANEKA thinks “Wellness First”.
Kaneka contributes to the sustainability of the earth,develops its business in a “wellness-first” direction,energizes people, adds vibrancy to business, and helps build a happier society.
To make the world more wellness-first.
Kaneka takes an innovative approach to science,and seeks to fulfil people’s dreams by offering a wide variety of solutions.

1

To our valued Shareholders.
Thank you for your continued support and interest in the Kaneka Group.
I am Kazuhiko Fujii, and I became President as of April 1st of this year.
I will do my best to meet your expectations and ask for your support
moving forward.
I am pleased to report on the Kaneka Group’s business activities for the
100th business period, from April 1, 2023 to March 31, 2024.
Looking at the overall performance for the Group, net sales were¥762,302 million, up 0.9% year on year, operating income was ¥32,579
million, down 7.1% year on year, and net income attributable to ownersof parent was ¥23,220 million, up 0.9% year on year.
The Company has decided to pay an annual dividend of ¥110 per share,taking overall account of its performance trend, dividend payout ratio,
and other factors. As we have already paid an interim dividend of ¥55
per share, the year-end dividend will therefore be ¥55 per share.
In the future, the natural environment around us will become increasingly
burdened, with human behavior possibly causing dangerous climatechange and mass extinctions.
The Earth’s life, our lives, and our universal understanding that “life is achemical reaction” are our purpose management we aim for at “KANEKAThe Dreamology Company—Make your dreams come true.”
We will promote “hybrid management” to develop creative and valuable
solutions through surprising combinations of Kaneka’s wide variety ofdifferent technologies.
By continuing to take on the challenge of R2B in the life science area,
we will accelerate transformation and growth to meet the expectationsof all our stakeholders and aim to become a highly regarded company.
In closing, I would like to ask for your continued support as we move
forward.

June, 2024

2

President andRepresentative Director

Kazuhiko Fujii

1. Business Developments and Results State of the Global Economy - Fragmentation and economic volatility In the current fiscal year (April 1, 2023 to March 31, 2024), although the COVID-19 pandemic ended during theperiod, the global economic outlook remained uncertain due to ongoing geopolitical risks such as the prolonged
Ukraine crisis and the outbreak of new conflicts in the Middle East. Amid monetary policy turmoil in the U.S. andEurope, which have been plagued by inflation, friction between the U.S. and China, and economic downturn in
China, the global economy has had a volatile year lacking a clear direction.
As for Japan, the yen continues to depreciate. Economic and monetary policies have stalled and GDP has fallen
to fourth place in the world, with a possibility of slipping to fifth place. These critical issues affecting national
development show no signs of ending.
The world is fragmented by country and region, and synchronized economies and growth scenarios are notforeseeable.
As we face such uncertain times, tossed about by “fragmentation and volatility”, we will refine our global activities
with local roots, which is our company’s DNA, and accelerate the implementation of new products andbusinesses with our research & development strategy of “one and only Kaneka R2B”.
We are refining our technology, updating our portfolio, and expanding our business.
Above all, it’s all about people.
 aneka Group’s Business Performance - Sales increased and profits decreased, but profits increased
 Ksignificantly in the second half Under these circumstances, Kaneka Group’s consolidated business performance for the fiscal year ended March
31, 2024 was as follows.
Consolidated net sales were ¥762,302 million (up 0.9% year-on-year),
Operating income was ¥32,579 million (down 7.1% year-on-year),Ordinary income was ¥29,222 million (down 9.8% year-on-year), andNet income attributable to owners of parent was ¥23,220 million (up 0.9% year-on-year).
Business performance for the fiscal year ended
March 31,2024(April 1,2023 to March 31,2024)
FY2022

FY2023

Net Sales

755,821762,302

Operating income

35,08732,579Ordinary income

32,411

29,222

Net income attributable toowners of parent

23,00823,2203(Millions of yen)
Difference(year-on-year)

6,480
0.9%
(2,508)(7.1%)(3,188)(9.8%)
212
0.9%

Net sales and operating income by business segments

(Millions of yen)
Net Sales

FY2022
3Q

1Q

2Q

Material SU

88,91983,975

Quality of Life SU

45,000

Health Care SU
Nutrition SU

FY2023
3Q

4Q

Total

1Q

2Q

77,812

83,147

333,854

77,65978,81442,194

43,812

41,758

172,766

40,878

16,62317,36918,65818,13470,786

41,87944,09146,01845,350

316

231

240

192,739

187,863

186,541

1Q

2Q

FY2022
3Q

Material SU

10,756

7,947

Quality of Life SU

4,600

Health Care SU

Others
Total

4Q

Total

81,44484,982322,90243,88046,63844,785

176,182

17,74518,44817,20921,45274,856

177,339

46,03746,00649,03846,099187,182

286

1,074

419

226

280

252

1,178

188,678755,821

182,740

187,376

194,611

197,574

762,302

FY2023
3Q

4Q

Total

Difference(year-on year)(10,952)(3.3%)
3,415
2.0%
4,069
5.7%
9,843
5.6%
103
9.7%
6,480
0.9%

Operating income
4Q

Total

1Q

2Q

3,767

4,978

27,449

5,513

6,610

6,996

8,375

27,495

4,069

4,386

3,075

16,131

2,939

4,159

4,655

3,607

15,361

3,856

3,653

4,471

3,701

15,682

2,967

2,926

2,451

4,596

12,941

Nutrition SU

806

1,296

2,290

3,192

7,585

2,277

2,298

3,820

3,680

12,076

Others

186

95

112

159

554

288

101

151

125

667

(7,994)(8,460)(8,221)(7,640)(32,316)(8,381)(9,093)(9,070)(9,417)(35,963)

12,212

8,601

6,808

7,465

35,087

5,603

7,002

9,004

10,96832,579Adjustment
Total

4

Difference(year-on year)

45
0.2%
(769)
(4.8%)(2,740)(17.5%)
4,490
59.2%
113
20.4%
(3,646)—(2,508)(7.1%)

 Remarks on the Group-wide Business Performance Rapid recovery of business performance
In the current fiscal year ended March 31, 2024, Group-wide business performance was characterized byoperating income that bottomed out at ¥5.6 billion in 1Q (April 1 to June 30, 2023), and the pace of recovery
accelerated in each successive quarter, to ¥7.0 billion in 2Q (July 1 to September 30, 2023), ¥9.0 billion in 3Q(October 1 to December 31, 2023), and ¥11.0 billion in 4Q (January 1 to March 31, 2024).
Although substantial negative forces remain, such as the inflation-driven downturn in construction demand inEurope and the U.S. and inventory adjustments in the electronics market, business performance abruptly
turned towards profit recovery in the second half. Despite a sluggish first half primarily due to extremely
volatile post-COVID-19 fluctuations in demand, strong momentum returned to each Solutions Vehicle in thesecond half.
In particular, operating income in 4Q reached ¥11.0 billion thanks to contributions from overseas business
Solutions Vehicles such as Modifiers, Modified Silicone polymers, and E & I Technology, which are targeting
results in R2B, and Supplemental Nutrition and Foods (Nutrition Solutions Unit), which are shifting towards adevelopment strategy utilizing unique and niche technologies not found anywhere else. Business performancein Medical grew steadily, and Vinyls and Chlor-Alkali and Foam & Residential Techs have also gotten out of theworst period.
FY2023 operating income 1H vs 2H comparison

2H operating income YoY comparisonMaterial SU
Quality of Life SU
Health Care SU
Nutrition SU
Total(Billions of yen)

Operating income
FY2022
FY2023Difference
1H
2H
1H
2H
18.7
8.7
12.1
15.4
3.2
8.7
7.5
7.1
8.3
1.2
7.5
8.2
5.9
7.0
1.2
2.1
5.5
4.6
7.5
2.9
20.8
14.3
12.6
20.0
7.4

Material SU
Quality of Life SU
Health Care SU
Nutrition SU
Total(Billions of yen)

Operating income
FY2022 FY2023
Difference
2H
2H
8.7
15.4
6.6
7.5
8.3
0.8
8.2
7.0
(1.1)
5.5
7.5
2.0
14.3
20.0
5.7

 Leading-Edge Businesses Driving Kaneka’s Portfolio Transformation
For Medical, Supplemental Nutrition, Modified Silicone polymers, E & I Technology, and PV & Energy
management, our differentiated and unique technologies and open innovation bore fruit, resulting in steady
growth in performance.
For Medical, business performance grew steadily. Since technological sophistication is the driving force
behind the development of this business, we are actively engaged in open innovation, including M&A andtechnological alliances, leveraging our Japanese business model that is highly trusted by physicians. With
overseas markets such as the U.S., China, and Asia as our next strategic move, we are focusing all our efforts
on strengthening our R2B capabilities and restructuring our sales system. We aim to develop the Medical
business into a driver of company growth.
For Pharma, demand adjustment continued and performance remained sluggish, but 4Q saw a significant
shift toward recovery. In Bio-CDMO and small molecule pharmaceuticals, joint development activities with5

customers have progressed and momentum has returned. Looking ahead to the next fiscal year, we are
aggressively pursuing further large projects in both domestic and overseas markets.
 Strong Performance of Foundation Businesses
Modifiers, which experienced a significant drop of demand in the European, U.S., and Asian markets due topost-COVID-19 volatility, has gotten out of a period of excess market inventory and global supply-demand
imbalance. Comparisons between the first and second half of the current fiscal year and comparisons
between the current and the previous fiscal year’s second half both show significant profit growth.
Like Modifiers, Vinyls and Chlor-Alkali and Foam & Residential Techs, which are focused on activities to createa scalable global niche market by strengthening technology differentiation capabilities, have also emerged
from the worst period. After suffering from a collapse of supply and demand in the general-purpose market
and deteriorated market conditions, Vinyls and Chlor-Alkali has maintained stable performance, although it
has not returned to the profitability of the COVID-19 period when the supply-demand balance was tight.
Performance Fibers aimed for recovery after bottoming out in 1Q, but due to prolonged inflation and currency
depreciation in African countries, 4Q was a temporary demand adjustment phase. We are diligently pursuing
R2B activities that will enable us to offer unique and distinctive fibers that are only possible with Kanekalon byenhancing its functionality. In the hair accessories field, we are expanding our domain and strengthening salesin Sub-Saharan Africa and North, Central, and South America, with Nigeria as our focal point.
For Foods & Agris, profitability improved significantly due to further progress in the sales shift to high-valueadded products and expansion of profit margin. We plan to maintain this high level of performance. New
businesses such as Pur Natur dairy products, coenzyme Q10 yogurt and gummies, organic A2 milk, and
BENOIT NIHANT Belgian chocolate are running strong and leading the portfolio transformation in the Foods
business.
 Progress of Investment Plan for Growth
For Medical, a new production facility for blood purification devices in Tomatoh, Hokkaido, is scheduled tostart operation in 2Q of the fiscal year ending March 31, 2025. Furthermore, we expanded our lineup ofcatheter products with open innovation, such as by acquiring a company with biodegradable magnesium
stent technology and by importing and selling stents used to retrieve blood clots.
For Pharma, construction is proceeding as planned for Kaneka Eurogentec S.A.’s production facility for
mRNA, which is expected to grow at a high rate for adoption in therapeutics for genetic diseases and cancer.
In the Material Solutions Unit, construction of the demonstration plant for the mass production of KANEKA
Biodegradable Polymer Green Planet™ that aims to protect the global environment by reducing single-use
plastics, is progressing smoothly. In addition, the capacity expansion of Modified Silicone polymers in
Belgium, where global demand is expected to increase, will be completed as planned this spring.
We have decided to make a major capital investment to decommission the coal boilers at Takasago. We willtake this opportunity of fuel conversion at our in-house power generation facilities, which employ an innovative
process, to further conserve energy and aim to go carbon neutral by 2050.
We will aggressively pursue investments that will accelerate the growth of our leading-edge businesses andstrengthen the base of our foundation businesses.
The operating performance by business segment was as follows:6

（Earthology Chemical Solution）

Material Solutions Unit
Material Value CreatorTo support the advancement of life and the environment by drawing out the richness of materials

This unit was affected by economic slowdown in Europe,
the U.S., and Asia, resulting in lower profits in the first half,
but profits increased significantly in the second half due tosupply and demand recovery. On a full-year basis, the unit
recovered to the previous year’s level.

For Vinyls and Chlor-Alkali, both PVC and caustic soda were affected by
the decline in the Asian market, but performance has been recovering
since 3Q.
For Modifiers, demand-supply adjustments continued throughout the year,
but demand has been recovering at all locations since 3Q, resulting in asignificant year-on-year increase in profits in the second half. Profitability improved as efforts to strengthen businesscompetitiveness made steady progress.
For Modified Silicone polymers, sales remained strong in response to its unique functional characteristics. We aim to expand
our business by fully leveraging our increased production capacity in Belgium to be completed this spring.
For Green Planet™, progress has been made in joint development with major brand holders and its adoption in new
applications increased.

（Earthology Chemical Solution）

Quality of Life Solutions Unit
Quality of Life Pathfinder

To produce the leading edge of the enhancement of the quality of life through the power of materials

This unit achieved higher sales and higher profits in Foam &Residential Techs, E & I Technology, and PV & Energy management,
but reported higher sales and lower profits overall due to ongoing
demand-supply adjustments in Performance Fibers.

For Foam & Residential Techs, profit margin improved, resulting in higher
sales and higher profits overall. Sales of polyolefin foam recovered in theautomobile sector and its adoption in EV applications has expanded.
For PV & Energy management, domestic sales of high-efficiency
photovoltaic modules for single homes were firm. The government’s
promotion of GX and the growing trend of municipal mandates regarding
the use of renewable energy drew further attention to our products. To stimulate demand for zero-energy building (ZEB), in
which walls and windows generate electricity, we established the joint sales company with Taisei Corporation.
For E & I Technology, polyimide shipments were affected by the adjustment of smartphone production in the first half of theyear, but demand has recovered since 3Q, especially in the Chinese market. Acrylic resins for large-screen TVs experienced atemporary demand adjustment, but have recovered since 4Q.
For Performance Fibers, demand was sluggish due to the significant impact of inflation and currency depreciation in African countries. We will
focus on stimulating end-user demand by strengthening marketing strategies and proactively introducing new high-performance products.
7

（Active Human Life Solution）

Health Care Solutions Unit
Medical Edge Explorer

To create a world where advanced medical means are available to as many people as possible

In this unit, the Medical business expanded steadily, while
the Pharma business was affected by shipment adjustments
through 3Q. Overall, sales increased and profits decreased.
For Medical, the new production facility for blood purification devices in
Hokkaido is scheduled to start operation. We will continue to actively
invest management resources.
Pharma experienced longer-than-expected demand adjustments fromsmall molecule pharmaceutical and biopharmaceutical customers, but
demand has been on a recovery trend since 4Q. For mRNA, we will
strengthen the production system and focus on its adoption intherapeutics for genetic diseases and cancer.

（Active Human Life Solution）

Nutrition Solutions Unit

Nutrition Value Chain Innovator
To re-innovate food and healthThis unit recorded substantial increases in both sales andprofits owing to the continued strong performance of Foods
and Supplemental Nutrition.
For Supplemental Nutrition, the sales of the active form of coenzyme Q10
remained firm in the U.S. Sales expanded in Asia and Oceania. For the
probiotics business, sales are also expanding. Sales expansion in the U.S.,
the biggest market, is a challenge, and we will focus on launching a varietyof new products and reinforcing our production base.
For Foods & Agris, profit margin improved and earnings grew substantially.
We aim to expand business by aggressively promoting high value-added“Business to Consumer” businesses including organic dairy products andyogurt.

8

2. Issues to be AddressedKaneka’s Purpose Management
The natural environment is being increasingly overburdened and human activities may cause dangerous
climate change and mass extinction. To reduce this risk, we must further our understanding of nature andrapidly deploy the appropriate technologies. This perspective is our purpose management, “KANEKA The
Dreamology Company −Make your dreams come true−,”. We are refining our technology in three domains: theenvironmental and energy crisis, the food crisis, and the wellness (better living) crisis with an aspiration toprovide optimal solutions through their social implementation.
Hybrid Management
Innovation is “a combination that does things in a different way.” Combining different things in different
business fields in a new way. We call this “hybrid management.” We will continue to solve social problems
through hybrid management, which creates creative and valuable solutions through surprising combinations of
Kaneka’s wide variety of different technologies.
R2B+P - Accelerating the Flow from Research to Business
Shifting from “R&B+P” to “R2B+P,” we will promote the fusion of research and business and further accelerate
the flow from research to business. We will create unique and superior materials and provide solutions to theglobal market. By strengthening our R2B+P initiative, which strongly integrates R2B and manufacturing, we will
focus on maximizing and monetizing our business with a manufacturing-first approach and increase the speed
and scale of our commercialization of new products.
Shift in Emphasis to Life Sciences
The definition of “life science” is the technologies and creative activities that use chemistry to make life on Earthhealthier. Kaneka’s “biomanufacturing,” such as the biodegradable polymer Green Planet™, genome editing
technology, biopharmaceuticals, regenerative medicine and cell therapy, organic dairy products business,
supplements, and fermentation culture process technology, PV technology, and medical devices are allconnected to the big “life,” that is, life on Earth. Kaneka will drive the transformation of its portfolio by taking on
the challenge of “R2B” in the life science area.
Think Global, Act Local
Our strength is our global network enabling business development deeply rooted in local communities. Our
mission is to deliver solutions all over the world to save human lives and resolve social issues, and we focus on
conducting local-based business (glocal business) by overcoming cultural differences. Our goal is to become acompany with a global presence. We will seek management resources from around the world and actively
promote M&A, technology and business alliances, and open innovation to transform our global businessstructure and achieve rapid growth.

9Diversity - New Value Creation and Women’s Participation
By going beyond attributes such as age, gender, nationality, and race, and tapping into diversity, we bring forth
new ideas. In this way, we aim to continue delivering unique Kaneka value that amazes the world. This is our
vision for diversity. In particular, we are working to promote the active participation of women and strengthen
the development of female leaders who will drive growth and change. Kaneka 1-on-1, which was introduced
and established based on the idea that “people grow through their work, while companies grow through theirpeople,” will evolve into a new stage, “Kaneka 1-on-1X,” to enhance individual growth and organizational
performance.
We will continue to promote “Trust & Respect - Human Driven Management” this year as well.
Carbon Neutral/DX Initiatives
We aim to reduce GHG emissions by 30% by 2030. Our goal is to achieve carbon neutral by 2050. We will
work to reduce energy consumption through fuel conversion of in-house power generation facilities andprocess innovation. We will also strengthen our DX initiatives and greatly accelerate value creation through
R2B+P. We will incorporate cutting-edge technology to evolve our production plants and build up
manufacturing sites in the future. We are also working on a company-wide digital platform concept using thelatest digital technology to promote operational innovation in research and development, sales, SCM, andback-office operations.

10

Health Care Solutions Unit

TOPICS

1Taking on the Challenge of R2B+P in the Life Science Area
—Large investments for further growth andproactive steps to open innovation—
Launch of a New Manufacturing Site forBlood Purification Devices
Our fifth manufacturing site, Tomatoh Manufacturing Site
(Hokkaido), was completed in May 2024 and is scheduled tostart operation in the first half of this fiscal year.
We plan to evolve the manufacturing site into one thatincorporates DX initiatives and state-of-the-art technology to
fully automate the new medical device production line andimprove productivity.
Furthermore, we will promote the introduction of renewableenergy using our own photovoltaic power generation systems
Tomatoh Manufacturing Site waiting to begin full-scale operation
and realize a manufacturing site with a low environmental
impact.

M&A to Expand and Enhance Solutions
We are combining our technologies with external technologies and tackling challenges in new areas as we strive toexpand and enhance solutions to meet growing demand worldwide for extending healthy life expectancy.
In November 2023, we acquired Japan Medical Device
Stent before
Technology Co., Ltd. (“JMDT”), making it a wholly
expansion
owned subsidiary. By integrating JMDT’s bioresorbablestents technology with our technologies, we aim to
Stent after
expand our business in the stent treatment area.
expansion

Expanding Product Lineup in the Neurovascular Field
In January 2024, we signed an exclusive distribution agreement with an Israeli company, Rapid Medical Ltd., for stent
retrievers (blood clot retrieval device) in Japan. We plan on growing our business in the neurovascular field byexpanding the product lineup and increasing the sale of i-ED COIL™, a coil for the embolization of cerebral
aneurysms.
We will provide solutions to health issues worldwide through the expansion of our medical business within theincreasingly important field of health care.
11Material Solutions Unit

TOPICS

2

Aiming to Be an Advanced Biomanufacturing Company—KANEKA Biodegradable Polymer Green Planet™—
Green Planet™ is a 100% biomass-derived biodegradable polymer developed by Kaneka based on our desire toprovide environmentally friendly solutions that do not depend on petroleum resources.
A key challenge in terms of promoting the use of Green Planet™ has been the difficulty in the molding process, but
amid developments in cultivation and compounding technology and in processing technology, solutions are now
emerging. In fiscal 2023, we continued to make progress in joint development with major brand holders and its
adoption in new applications increased.

Increasing adoption of Green Planet™ in various fields

Razors:Tokyu Hotels & Resorts Co., Ltd.
Gloves:S.T. CORPORATION

Food containers for JAL
international in-flight meals:
JALUX Inc.
Large-screen TV
cushioning material*:Sony Corporation* For Hong Kong and Taiwan.
Different depending on area and model.

Development of Green Planet™ Culture Technology Using CO2 as a Raw Material
We are conducting research and development to produce Green Planet™ by using CO2 as a raw material instead ofvegetable oil. This research has been selected as a Green Innovation Fund Project promoted by the government, andwe are working to realize the construction of a demonstration plant.
Based on our mission of “KANEKA thinks ‘Wellness First,’” we deliver value globally as a solution provider. We willcontinue to contribute to bringing about a sustainable society as well as solutions to plastic pollution by promoting
the use of Green Planet™.

12

Quality of Life Solutions Unit

TOPICS

3Contributing to People’s Health and the Enrichment of Lives
OLED Lighting Donated to Tokyo National Museum
We signed a basic agreement with Tokyo National Museum operated by the
National Institutes for Cultural Heritage, regarding the donation of OLED lighting
in January 2024. We will be replacing the ceiling lighting in the exhibition rooms
and exhibition cases on the 2nd floor of the museum’s main building going
forward. OLED lighting is less likely to cast shadows giving high visibility, anddoes not emit ultraviolet rays, making it ideal for preserving artworks. In the
future, we will be conducting joint research with Tokyo National Museum topromote the widespread use and branding of OLED lighting.
“Pine Forest” (replicated) lit by OLED lighting

Start of Project to Enhance Quality of Sleep

OLED lighting installed inresidential unit at
Sustainabranche Hongyotoku(Tokyo National Museum main building)In joint collaboration with HASEKO Corporation (Headquarters: Minato-ku, Tokyo;
President: Kazuo Ikegami), we have started to verify the effects of using OLED lighting in
the rental apartment project “Sustainabranche Hongyotoku” (Ichikawa City, Chiba) on
falling asleep and reducing fatigue. In addition to the surface-emitting light source of
OLED lighting that gives off a gentle light and high visibility, the results of OLED lighting
having effects on a good night’s sleep and fatigue reduction will promote wellbeing
through the lighting environment and expansion of OLED usage in condominium units.

Accelerating the Development and Diffusion of Attractive Renewable Energy Products
Kaneka Corporation and TAISEI CORPORATION (Headquarters: Shinjuku-ku,
Tokyo; President: Yoshiro Aikawa) have established G.G. Energy Corporation
for the purpose of a joint business to sell Green Multi Solar. Green Multi Solar isa photovoltaic power generation system integrated with external walls andwindows on buildings, co-developed by the two companies in 2019. G.G.
Energy Corporation started full-scale operations in April this year.
The two companies will proactively propose this product to environmentallyconscious companies and government facilities as an energy-creating
technology for new and renovated buildings.
13

Glass-integrated power generation system
Example of T-GreenTM Multi Solar
installation(Left: see-through type, Right: color type)Sustainability

TOPICS

4

Accelerating Fuel Conversion to Become Carbon Neutral—Kaneka’s aim to achieve carbon neutrality—
To reduce GHG emissions by 30% by 2030 (compared to fiscal 2013) and become carbon neutral by 2050, we areworking to reduce energy consumption through fuel conversion of our in-house power generation facilities andprocess innovation.
In fiscal 2023, we decided to make a major capital investment to decommission the coal boilers at Takasago
Manufacturing Site.
In addition, we added 180,000 tons to the cumulative total of 540,000 tons for reduction themes identified in fiscal
2022, creating a cumulative potential of 720,000 tons.
Additional potential

180,000 tons

Fiscal 2013
GHG emissions(actual)2023 potential

720,000 tons
Decarbonization (310,000 tons)
3 years ahead of scheduleSpecific Initiatives
Fuel conversion

2022 potential

540,000 tons

480,000

To move our decarbonization ahead ofschedule by three years (expecting toachieve it by 2027 instead of 2030), theTakasago Manufacturing Site will install a
new gas turbine co-generation system in
2027.

Scope2*

Scope2*

Use of renewable energy, low CO2 emission
factor for electricity and steam power

600,000

600,000

Scope1

950,000

1.08
milliontons

Scope1

tons

tons

tons

tons

2013

2027

2030

Total 1.55 million tons

2050
2030 GHG emissions target

Total 1.08 million tons
30% reduction
compared to fiscal 2013

* Since the CO 2 emission factor for electric power companies is subject to change, we expect ouremissions to be equivalent to those of fiscal 2013.

14

Kaneka Malaysia will switch to biomassderived steam in 2025. Kaneka Group will
expand the installation of in-house
photovoltaic power generation systems
on plants and other premises in Japanand overseas as we promote the use ofrenewable energy.
At our overseas
plants, we plan touse a low CO2
emission factor forelectricity.

The Dreamology Company－Make your dreams come true －